RVL Pharmaceuticals plc

RVLPQ

IE00BF2HDL56

Pharmaceuticals

Delayed OTC Markets Other stock markets 09:48:55 2024-05-22 EDT			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		0.00%	-96.67%

04-12	North American Morning Briefing : Big Banks Kick -2-	DJ
03-21	North American Morning Briefing : Investors -2-	DJ

RVL Pharmaceuticals plc Provides Net Sales Guidance for the Fourth Quarter of 2022

January 19, 2022 at 06:50 am

RVL Pharmaceuticals plc provided net sales guidance for the fourth quarter of 2022. The company is targeting net sales for the fourth quarter of 2022 to be between $20 million and $25 million combined between eyecare and medical aesthetics.

Latest news about RVL Pharmaceuticals plc

North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
North American Morning Briefing : Investors -2-	03-21	DJ
North American Morning Briefing : TSMC Results -2-	01-18	DJ
North American Morning Briefing : Focus Fixed on Latest Inflation Print	01-11	DJ
North American Morning Briefing : S&P 500 Futures -2-	01-04	DJ
North American Morning Briefing : S&P 500 Futures Just Shy of Record High	12-28	DJ
North American Morning Briefing : Stock Futures -2-	12-21	DJ
North American Morning Briefing : Dow Set For New -2-	12-14	DJ
North American Morning Briefing : Stock Futures Struggle to Extend Rally Ahead of More Jobs Data	12-07	DJ
RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from S&P TMI Index	23-10-25	CI
RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from NASDAQ Composite Index	23-10-20	CI
Health Care Down as Risk Aversion Hurts Biotech -- Health Care Roundup	23-10-12	DJ
Sector Update: Health Care Stocks Decline in Late Afternoon	23-10-12	MT
Top Midday Decliners	23-10-12	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	23-10-12	MT
RVL Pharmaceuticals Subsidiaries File for Prepackaged Chapter 11 Change of Control to Lenders	23-10-12	MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29	MT
Top Premarket Gainers	23-09-29	MT
RVL Pharmaceuticals plc Announces Resignation of Joaquin Benes and Juan Vergez from the Board of Directors	23-09-22	CI
HC Wainwright Adjusts RVL Pharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	23-08-21	MT
Sector Update: Health Care Stocks Decreasing Late Afternoon	23-08-16	MT
Sector Update: Health Care	23-08-16	MT
Top Midday Decliners	23-08-16	MT
Transcript : RVL Pharmaceuticals plc, Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Earnings Flash (RVLP) RVL PHARMACEUTICALS Posts Q2 Revenue $8.3M, vs. Street Est of $10.3M	23-08-14	MT

Chart RVL Pharmaceuticals plc

Duration

Period

More charts

Company Profile

RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
RVL PHARMACEUTICALS PLC	-96.67%	11.14K
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.80%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.45%	14.52B
INCYTE CORPORATION	-8.11%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B

Biopharmaceuticals